Symbotic Inc vs Twist Bioscience Corp — how do they compare? Symbotic Inc trades at $43 (market cap $5.19B), while Twist Bioscience Corp trades at $88.31 (market cap $5.45B). The key difference: Symbotic Inc and Twist Bioscience Corp are close in size by market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Symbotic Inc nearer its low. Which is the better fit depends on your goals.
| SYM | TWST | |
|---|---|---|
Market Cap | $5.19B | $5.45B |
Sector | Technology | Health |
52-Week High | $87.30 | $102.88 |
52-Week Low | $38.57 | $24.16 |
Enterprise Value | $3.18B | $5.37B |
Signals from Pluang's Aura AI — not financial advice
SYM trades at $40.83, down 1.02% with bearish technical signals despite recent earnings beats. The company shows revenue growth potential with $2.25B in 2025 revenue and improving margins, though net income remains negative. Analyst consensus is bullish with a $57.50 price target, while technical indicators show oversold conditions with RSI at 29.43. Recent news highlights Symbotic's positioning in warehouse robotics and AI automation.
The stock presents a growth opportunity in the expanding warehouse automation market, supported by strong analyst buy ratings and improving financial trends. Key risks include continued negative profitability, high valuation multiples, and competitive pressures in the robotics sector. Near-term catalysts include Q2 2026 earnings and execution on the company's $1.1B projected net cash flow for 2026.
TWST trades at $95.86, up 2.14% today, with a bullish technical signal and strong institutional interest. Revenue growth is robust, rising from $204M in 2022 to $377M in 2025, though the company remains unprofitable with a net income margin of -19.85%. Recent news highlights AI-driven collaborations and earnings beats, but cash flow trends show persistent operational losses.
The outlook is mixed; analyst consensus is bullish with a $91.63 price target, but profitability challenges and negative cash flows pose significant risks. Investment opportunity lies in continued revenue expansion and AI partnerships, while execution risks and high valuations require caution.
Trailing returns across standard periods
Latest headlines on both assets
Symbotic is an automation technology leader that provides an end-to-end, A.I.-powered robotic platform for large-scale warehouse operations. By utilizing untethered, high-speed autonomous bots and sophisticated vision systems, Symbotic transforms traditional distribution centers into high-density strategic assets. The company serves the world’s largest retailers and wholesalers—most notably Walmart—while expanding into 'Warehouse-as-a-Service' through its GreenBox joint venture to democratize advanced automation for smaller enterprises.
Read more on SYM →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →